title: Endothelin-1 induces liver vasoconstriction through both ETA and ETB receptors.
abstract: OBJECTIVE
  We investigated which endothelin receptors mediate the vasoconstrictive effects of endothelin-1 on liver circulation.
  
  
  METHODS
  An isolated perfused rat liver model in recirculation was used.
  
  
  RESULTS
  The perfusion of 10(-10) M endothelin-1 had no significant influence on the liver flow, whereas 10(-9) M endothelin-1 induced significant vasoconstriction, with flow dropping from 3.20 +/- 0.34 to 1.48 +/- 0.28 ml. min-1.g-1 liver tissue (p < 0.01 vs controls). The liver flow was interrupted following the perfusion of 10(-8) M endothelin-1. Sarafatoxin C and BQ 3020, two agonists of ETB receptor, had vasoconstrictive effects in this model. Sarafatoxin C decreased the liver flow in a dose-dependent manner, from 3.32 +/- 0.21 to 2.18 +/- 0.20, 1.60 +/- 0.09, and 1.01 +/- 0.06 ml.min-1. g-1, respectively, with 10(-9) M, 10(-8) M, and 10(-7) M. While BQ 123, an antagonist of ETA receptor, or BQ 788, an antagonist of ETB receptor, partially reversed the effect of 10(-9) M endothelin-1, the simultaneous administration of BQ 123 and BQ 788 completely reversed these effects.
  
  
  CONCLUSIONS
  These results indicate that the vasoconstrictive effects of endothelin-1 on the liver circulation are mediated through both ETA and ETB receptors.
authors.affiliation: Laboratoire de Recherche Chirurgicale, Faculté de Médecine Cochin-Port-Royal, Université paris V, France.
authors.forename: B
authors.initials: B
authors.lastname: Zhang
authors.forename: Y
authors.initials: Y
authors.lastname: Calmus
authors.forename: L
authors.initials: L
authors.lastname: Wen
authors.forename: P
authors.initials: P
authors.lastname: Sogni
authors.forename: S
authors.initials: S
authors.lastname: Lotersztajn
authors.forename: D
authors.initials: D
authors.lastname: Houssin
authors.forename: B
authors.initials: B
authors.lastname: Weill
mesh_terms: D000818:Animals; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000494:pharmacology*; D008102:Liver Circulation / Q000187:drug effects*; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin / Q000819:agonists / Q000502:physiology*; D014661:Vasoconstriction; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014757:Viper Venoms / Q000494:pharmacology
chemical_list: D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D009842:Oligopeptides; D010456:Peptides, Cyclic; D010880:Piperidines; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin; D014662:Vasoconstrictor Agents; D014757:Viper Venoms; C057354:sarafotoxins s6; C086539:BQ 788; C072247:cyclo(Trp-Asp-Pro-Val-Leu)